Method for examining central nervous system diseases and method for screening therapeutic agents
AssigneeTanabe Seiyaku Co., Ltd.
InventorsTsutomu Takagi, Naoya Sato, Masaya Tohyama
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for screening and identifying therapeutic agents or preventive agents for central nervous system diseases which comprises assaying a suppressing effect of a test substance on an expression of a splicing variant transcribed from presenilin-2 gene and to a method for examining central nervous system diseases which comprises detecting an expression of a splicing variant transcribed from presenilin-2 gene in a test sample originated from an animal individual.
Claims22
A method for screening and identifying a therapeutic agent or preventive agent for central nervous system disease which comprises assaying a suppressing effect of a test substance on an expression of a splicing variant transcribed from presenilin-2 gene.
A therapeutic agent or preventive agent for Alzheimer's disease having an effect of suppressing an expression of a splicing variant transcribed from presenilin-2 gene and lacking exon 5.
A method for detecting a splicing variant lacking exon 5 of presenilin-2 gene comprising detecting nucleic acid containing at least the 705th and 706th bases in the base sequence described in SEQ ID NO:
- 2.
A method for detecting a splicing variant lacking exon 3 of presenilin-2 gene comprising detecting nucleic acid containing at least the 329th and 330th bases in the base sequence described in SEQ ID NO:
- 3.
A method for detecting a splicing variant lacking exon 3 and exon 4 of presenilin-2 gene and having a portion of an intron comprising detecting nucleic acid containing at least the 330th to 409th bases in the base sequence described in SEQ ID NO:
- 4.
A nucleic acid having a base sequence which is identical or complementary to a splicing variant lacking exon 5 of presenilin-2 gene.
A polypeptide originated from a splicing variant lacking exon 5 of presenilin-2 gene, said polypeptide either (1) having an amino acid sequence described in the bottom of SEQ ID NO:
- 5, or (2) having an amino acid sequence in which one or a plurality of the amino acid residues are added, deleted or substituted in an amino acid sequence described in SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.